Hypertension Diagnostics Stock Net Asset
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Hypertension Diagnostics' long-term financial health and intrinsic value.
Hypertension |
Hypertension Diagnostics Company Net Asset Analysis
Hypertension Diagnostics' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Hypertension Diagnostics Net Asset | 1.28 M |
Most of Hypertension Diagnostics' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hypertension Diagnostics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
CompetitionBased on the recorded statements, Hypertension Diagnostics has a Net Asset of 1.28 M. This is much higher than that of the Health Care Equipment & Supplies sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Hypertension Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Hypertension Diagnostics' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Hypertension Diagnostics could also be used in its relative valuation, which is a method of valuing Hypertension Diagnostics by comparing valuation metrics of similar companies.Hypertension Diagnostics is currently under evaluation in net asset category among its peers.
Hypertension Fundamentals
| Return On Asset | 3.0E-4 | ||||
| Profit Margin | (0.03) % | ||||
| Operating Margin | 0.0002 % | ||||
| Current Valuation | 5.26 M | ||||
| Shares Outstanding | 52.39 M | ||||
| Price To Earning | (0.03) X | ||||
| Price To Sales | 0.15 X | ||||
| Revenue | 3.79 M | ||||
| Gross Profit | 954.47 K | ||||
| EBITDA | 72.29 K | ||||
| Net Income | (125.39 K) | ||||
| Cash And Equivalents | 5.66 K | ||||
| Total Debt | 4.69 M | ||||
| Current Ratio | 0.52 X | ||||
| Book Value Per Share | (0.09) X | ||||
| Cash Flow From Operations | (389.28 K) | ||||
| Earnings Per Share | (0) X | ||||
| Beta | -0.92 | ||||
| Market Capitalization | 730.42 K | ||||
| Total Asset | 1.28 M | ||||
| Retained Earnings | (30.68 M) | ||||
| Working Capital | (857 K) | ||||
| Current Asset | 277 K | ||||
| Current Liabilities | 1.13 M | ||||
| Z Score | -31.6 | ||||
| Net Asset | 1.28 M |
Currently Active Assets on Macroaxis
| USOI | Credit Suisse X Links | |
| ULTY | Tidal Trust II | |
| CONY | YieldMax N Option | |
| BCAT | BlackRock Capital Allocation | |
| PDI | Pimco Dynamic Income |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Other Consideration for investing in Hypertension Pink Sheet
If you are still planning to invest in Hypertension Diagnostics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Hypertension Diagnostics' history and understand the potential risks before investing.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |